A Probiotic That Reduces Atopic Skin

Wecare Probiotics Co., Ltd.32 enrolled

Overview

To assess the efficacy and safety of the use of probiotics as food supplements in reducing the SCORAD index in children with atopic skin compared with placebo. This is a randomized, placebo-controlled, double-blind clinical trial with 2 parallel groups, which will include 32 patients who attend some of the research centers. Patients will be randomized into one of the 2 study groups (allocation ratio 1: 1): Experimental group (Lactobacillus rhamnosus LRa05) and placebo group (placebo). The reduction of the SCORAD index, the number of sprouts in 12 weeks, the days of use of topical corticosteroids and one valuations of the skin condition (hydration).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

DOUBLE

Enrollment

Conditions

Atopic Skin Children

Interventions

Eligibility

Sex: ALLMin age: 2 YearsMax age: 14 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients with atopic dermatitis in the sprouts phase with a moderate SCORAD index (16-40). 2. Patients aged 2-14 years. Exclusion Criteria: * Patients intolerant to gluten, lactose or cow's milk protein. * Patients who change the type of diet during the study to improve their atopic dermatitis. * Patients with atopic dermatitis in remission phase (absence of sprouts and with SCORAD index = 0). * Patients with an allergy or intolerance to any of the ingredients in the formulation of the product under study. * Patients taking immunomodulators, topical or oral antibiotics, topical or oral antihistamines, oral corticosteroids or antineoplastics. * Subjects whose condition does not make them eligible for the study, according to the investigator.

Locations (2)

CAP Alhambra of Hospitalet de Llobregat

Barcelona, Spain

CAP La Mina Carrer Mar Sant Adrià de Besos